Anti-Human CD257 (BAFF) (Belimumab)

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Belimumab. Belimumab is a monoclonal antibody that specifically targets and inhibits B-lymphocyte stimulator (BLyS), also known as B-cell activating factor (BAFF).

CD257, commonly referred to as the BAFF, plays a crucial role in regulating B-cell survival, maturation, and differentiation by interacting with specific receptors such as TACI, BCMA, and BAFFR¹. Through these interactions, BAFF exerts anti-apoptotic effects that promote the survival of B cells, making it a key factor in the pathogenesis of autoimmune diseases and B-cell malignancies. Elevated levels of BAFF have been associated with conditions like systemic lupus erythematosus (SLE) and rheumatoid arthritis, where overactive B-cells contribute to disease progression. Targeting CD257/BAFF has emerged as a promising therapeutic strategy for managing such disorders, as it can disrupt the signaling pathways that maintain abnormal B-cell activity^1,2.

Belimumab, a monoclonal antibody, specifically inhibits BAFF (also known as BLyS). By neutralizing BAFF, Belimumab reduces the survival and activity of B- cells, thereby dampening the autoimmune response. It is primarily used to treat SLE and lupus nephritis, conditions characterized by excessive B-cell activation and inflammation^3,4.

BAFF is distributed throughout the body, with high expression in B cell lineage cells 3 . It is found in various tissues, including the blood, lymphatic tissues, and bone marrow.

TNFRSF13B/TACI, TNFRSF17/BCMA, BAFFR1, NF-kappa-B p50 subunit

1. Xu H, He X, Zhao W, et al. Clin Lab. 2012;58(5-6):411-418.
2. Ye W, Zhou Y, Xu B, et al. Medicine (Baltimore). 2019;98(51):e18407.
3. Figgett WA, Deliyanti D, Fairfax KA, Quah PS, Wilkinson-Berka JL, Mackay F. J Autoimmun. 2015;61:9-16.
4. Auyeung-Kim DJ, Devalaraja MN, Migone TS, Cai W, Chellman GJ. Reprod Toxicol.2009;28(4):443-455.
5. Belimumab Recombinant Monoclonal Antibody (MA5-41860). Accessed September 28, 2024. https://www.thermofisher.com/antibody/product/Belimumab-Antibody-Recombinant-Monoclonal/MA5-41860